An inherited deficiency of arylsulfatase A (ASA) causes the lysosomal storage disease metachromatic leukodystrophy (MLD) characterized by massive intralysosomal storage of the acidic glycosphingolipid sulfatide and progressive demyelination. Lyso-sulfatide, which differs from sulfatide by the lack of the N-linked fatty acid, also accumulates in MLD and is considered a key driver of pathology although its concentrations are far below sulfatide levels. However, the metabolic origin of lyso-sulfatide is unknown. We show here that ASA-deficient murine macrophages and microglial cells express an endo-N-deacylase that cleaves the N-linked fatty acid from sulfatide. An ASA-deficient astrocytoma cell line devoid of this activity was used to identify the enzyme by overexpressing 13 deacylases with potentially matching substrate specificities. Hydrolysis of sulfatide was detected only in cells overexpressing the enzyme fatty acid amide hydrolase (FAAH). A cell-free assay with recombinant FAAH confirmed the novel role of this enzyme in sulfatide hydrolysis. Consistent with the in vitro data, deletion of FAAH lowered lyso-sulfatide levels in a mouse model of MLD. Regardless of the established cytotoxicity of lyso-sulfatide and the anti-inflammatory effects of FAAH inhibition seen in mouse models of several neurological diseases, genetic inactivation of FAAH did not mitigate, but rather exacerbated the disease phenotype of MLD mice. This unexpected finding was reflected by worsening of rotarod performance, increase of anxiety-related exploratory activity, aggravation of peripheral neuropathy, and reduced life expectancy. Thus, we conclude that FAAH has a protective function in MLD and may represent a novel therapeutic target for treatment of this fatal condition.

Glycosphingolipids (GSLs) consist of the amino alcohol sphingosine or a related sphingoid base that is linked to a fatty acid via an amide bond and to a saccharide head group via an O-glycosidic linkage (1). The saccharide moiety of the acidic GSL sulfatide (3-O-sulfogalactosylceramide), a key component of myelin sheaths, is a sulfated galactosyl residue. Sulfatide is degraded in the lysosomal compartment by an ordered sequence of reactions, starting with desulfation through arylsulfatase A (ASA; EC 3.1.6.8), then removal of the galactosyl residue through galactosylceramidase (GALC; EC 3.2.1.46), and eventually cleavage of the N-linked fatty acid through acid ceramidase (ASAH1; EC 3.5.1.23). The hydrolytic products, sulfate, galactose, fatty acid, and sphingosine, are exported from the lysosome for reutilization. Lack of either ASA, GALC, or ASAH1 results in a fatal lysosomal storage disease designated as metachromatic leukodystrophy (MLD; OMIM 250100), globoid cell leukodystrophy (Krabbe disease; OMIM 245200), and Farber disease (OMIM 228000), respectively (2). They are characterized by intralysosomal accumulation of sulfatide, galactosylceramide (except CNS), and ceramide, respectively.

Lyso-sulfatide emerges as a minor storage product in the nervous system of MLD patients and mouse models of the disease (3). It differs from sulfatide by the absence of the N-linked fatty acid. The well-established cytotoxicity of this and related lyso-GSLs gave rise to a hypothesis that the lyso-forms, rather than the parental GSLs themselves, are key drivers of pathology in GSL storage diseases (4). Micromolar concentrations of lyso-sulfatide, for example, inhibit protein kinase C, cytochrome c oxidase activity, and migration of neuronal precursor cells via calcium-mediated process collapse (5–7). The origin of lyso-GSLs has been debated for a long time. Recent genetic and pharmacological data suggest that ASAH1 has a broader substrate specificity than initially supposed and deacylates not only ceramide, but also certain GSLs (8). For sulfatide, however, cleavage by ASAH1 could not be demonstrated so far. Alternatively, an anabolic source of lyso-sulfatide due to the accidental sulfation of psychosine (instead of galactosylceramide) by the galactose-3-sulfotransferase-1 has been proposed (9). On the other hand, two independent studies indicated degradation of sulfatide by unidentified nonlysosomal hydrolase(s) that in retrospect, although not proven, might be enzyme(s) with endo-N-deacylase activity (10, 11).

The main challenge in identifying such an endo-N-deacylase is that it might accept and convert sulfatide only as a secondary substrate and with a low catalytic efficiency $k_{cat}/K_m$. Analytical tools of high sensitivity will be required to demonstrate such a side reaction that might become physiologically relevant only if sulfatide accumulates to supraphysiologically levels.
Furthermore, the sought enzyme could be nonlysosomal, as lysosomally stored GSLs might shuttle to other cellular membranes via transporters (1) or interorganelle membrane contact sites (12). Here we report in vitro and in vivo experiments leading to the identification of a so far unrecognized sulfatide-hydrolyzing activity of fatty acid amide hydrolase (FAAH), an endoplasmic reticulum-localized amidase renowned for its function in the endocannabinoid metabolism.

Results

Optimization of sulfatide loading by translipofection

Cultured cells take up fluorescently or radioactively labeled GSLs from the medium and target them to lysosomes for degradation. Such cell loading assays are an established means to diagnose GSL storage diseases and to analyze the intracellular degradation pathways of GSLs. To increase the sensitivity of sulfatide loading assays, we exploited the negative charge of its sulfate group and tested cationic cell transfection reagents on their ability to promote cellular uptake. Complexation of NBD-labeled sulfatide with FuGENE HD proved to be more efficient with regard to internalization efficacy and cell viability than other cationic transfection reagents and previously published methods of complexation with BSA or packaging in synthetic lipoprotein particles (Fig. 1, A and B). Compared with the classical BSA complexation method, uptake of NBD-sulfatide was three- to four-fold increased. We designate this novel loading method as translipofection.

To evaluate the dissemination of fluorescently labeled sulfatide and its breakdown products on a subcellular level, wild-type and ASA-deficient cells were translipofected and analyzed by life-cell fluorescence microscopy. For this purpose we used two astrocytoma cell lines derived from wild-type mouse brain (11+/+C1) and ASA-knockout mouse brain (17−/−A1), respectively (13). To circumvent the low photostability of NBD, making long-term in vivo imaging difficult, sulfatide carrying an N-linked fatty acid with a more stable BODIPY 500/510 fluorophore (green) was synthesized (14). Cells were costained with the Golgi marker BODIPY-TR-ceramide (red). In wild-type 11+/+A1 cells, the green fluorescence of translipofected BODIPY 500/510-labeled sulfatide shifted from perinuclear vesicular structures, probably representing endosomes and lysosomes, through the Golgi apparatus to diffusely stained cellular compartments (Fig. 1C, lower panel). This redistribution can be explained by intralysosomal degradation of sulfatide to ceramide, its cleavage by ASAH1, export of the liberated BODIPY 500/510-labeled fatty acid to the ER, and reincorporation into complex phospho- and sphingolipids passing the

Figure 1. Loading of astrocytoma cells with fluorescently labeled sulfatide. A, cellular uptake of NBD sulfatide by ASA-deficient 17−/−A1 cells using three different loading protocols. For each condition incubation medium (left panel) was evenly distributed to three dishes (#1, 2, 3) that were analyzed separately (right panel). Fluorescence scanning of cellular lipid extracts separated by TLC reveals that translipofection with FuGENE HD transfection reagent is more efficient than sLDL- and BSA-mediated internalization. B, uptake of NBD sulfatide after preincubation with BSA, cationic polymers (Turbofect, ExGen 500), and cationic lipids (Lipofectamine 2000, FuGENE HD), respectively. C, fluorescence microscopy of ASA-deficient 17−/−A1 astrocytoma cells (upper panel) and wild-type 11+/+C1 cells (lower panel) at different times after translipofection of BODIPY 500/510-labeled sulfatide (green). Before sulfatide loading, cells were preincubated with the Golgi marker BODIPY-TR-ceramide (red). Appearing colocalizations (yellow) of BODIPY 500/510 and BODIPY-TR are indicated by yellow arrows. All cells are shown at identical magnification. The scale bar represents 10 μm.
Golgi apparatus to various cellular membranes. Due to the lack of ASA, BODIPY-labeled sulfatide cannot be hydrolyzed in 17−/−A1 cells causing accumulation of the green fluorescence in the endosomal/lysosomal compartment (Fig. 1C, upper panel; timepoint 0.5 and 1.5 h). Notably, also in this condition BODIPY 500/510-labeled sulfatide (or sulfatide-derived lipids) eventually escaped from lysosomal entrapment and reached the Golgi apparatus. Compared with wild-type cells, this redistribution was, however, substantially retarded and Golgi localization of BODIPY 500/510 could be seen 4 h after translipofection for the first time. Similar kinetics of redistribution were obtained for NBD-labeled sulfatide (not shown).

**Translipofection of human fibroblasts**

To characterize the fluorescing intermediates biochemically, lipid extracts of translipofected cells were separated by thin layer chromatography (TLC) and the chromatograms were scanned with a FLA-5100 fluorescence scanner showing a limit of detection around 10 fmol NBD per band. In a first experiment, wild-type human fibroblasts were translipofected. After 6 h, sulfatide (undegraded), galactosylceramide, ceramide, and free fatty acids could be identified by coseparation of NBD-labelled standards (Fig. 2A). Liberated NBD-labeled fatty acids were also reincorporated into composite lipids representing sphingolipids and phosphoglycerolipids as suggested by their Rf values and differential resistance to mild alkaline hydrolysis (not shown). Interestingly, signals were much more intense in lipid extracts from the medium than in cellular extracts indicating efficient export of NBD-containing metabolites probably via ATP-binding cassette transporters (15). This allowed us to investigate the intracellular metabolism of NBD sulfatide by analyzing conditioned medium in all following experiments.

![Figure 2. Translipofection of cells with NBD-sulfatide carrying an N-linked fatty acid with terminal (omega) fluorophore.](image-url)
**FAAH-deficient MLD-mice**

In a next experiment cells from a juvenile MLD patient with the disease-causing mutation p.P426L (“allele A”) (16) were translipofected. This mutation results in a residual ASA activity below 5% of normal. Importantly, signals for NBD-labeled galactosylceramide, ceramide, and fatty acid, albeit being very faint, were still discernible (Fig. 2B, second lane). Thus, translipofection of NBD sulfatide allows to measure also a low residual turnover of sulfatide.

**Sulfatide-hydrolyzing endo-N-deacylase activity of murine microglia and macrophages**

Next, we compared the sulfatide catabolism of the two murine astrocytoma cell lines 11+/+C1 and 17−/−A1. ASA-expressing 11+/+C1 cells were able to liberate the NBD-labeled fatty acid (Fig. 2C, arrow) indicating sulfatide degradation. In contrast, no fatty acid signal was discernible for 17−/−A1 cells. This reflects a complete blockade of the sulfatide catabolism in these ASA-deficient astrocytoma cells.

To investigate the sulfatide catabolism of ASA-deficient macrophages and microglial cells, we translipofected primary bone-marrow-derived macrophages and brain microglial cells isolated from ASA knockout mice. Surprisingly and in contrast to 17−/−A1 cells, both cell types released significant amounts of the NBD-labeled fatty acid (Fig. 2, D and E, arrows). Furthermore, NBD-galactosylceramide representing a prominent catabolic intermediate of the lysosomal degradative pathway in wild-type cells (Fig. 2, A–C) was undetectable. Taken together, these observations pointed toward an ASA-independent pathway of sulfatide degradation in macrophages and microglial cells involving direct deacylation (Fig. 3A).

**Selection of potential sulfatide-hydrolyzing endo-N-deacylases**

In an attempt to identify the sulfatide-hydrolyzing endo-N-deacylase activity of macrophages and microglial cells, published enzyme data were evaluated. Hydrolases with possibly matching substrate specificities acting on carbon-nitrogen bonds of peptides (E.C. 3.4) or other linear amides (E.C. 3.5.1) were selected from the BRENDA database (https://www.brenda-enzymes.org/) by applying one of the following three criteria. (i) lysosomal localization (according to Ref (17)) and high expression in cells of the monocyte/macrophage/microglial lineage (http://genevisible.com). Enzymes with complex substrate specificity requirements that could not be brought into compliance with the molecular structure of sulfatide were arbitrarily omitted. This led to the elimination of, e.g., cathepsins with endopeptidase activity (see Tables S2–S4). (ii) Nonlysosomal enzymes being evolutionary related to the selected lysosomal enzymes or have a very similar substrate specificity. Proteases were omitted to reduce the number of candidates (see Table S5). (iii) Enzymes with sequence similarities to the putative active site of sphingolipid ceramide N-deacylase from Shewanella algae (amino acids 516–643) (18) or Pseudomonas sp. TK-4 (amino acids 119–186; https://patents.google.com/patent/US6821761B2), two bacterial endo-N-deaclyases accepting complex GSLs as substrates. BlastP (https://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to compare the active sites with human nonredundant protein sequences and revealed weak similarities with dipeptidase I (DPEP1, 24% identity) and cathepsin S (CTSS, 34% identity), respectively (Fig. S1). Figure 3B lists the 13 candidates resulting from the selection procedure. The full-length cDNAs of the candidates were cloned into the eukaryotic expression plasmid pcDNA3.

**Evaluation of enzyme candidates by translipofection of 17−/−A1 cells**

Because ASA-deficient 17−/−A1 astrocytoma cells are not capable to degrade NBD sulfatide (Fig. 2C), they could be utilized to evaluate alternate sulfatide-hydrolyzing pathways using transgenic expression of ectopic deacylases. For this purpose, 17−/−A1 cells were transiently transfected with the candidate enzymes (Fig. 3B), translipofected with NBD sulfatide, and the release of NBD fatty acid to the medium was analyzed by high-performance liquid chromatography (HPLC). As a control, 17−/−A1 cells were metabolically corrected by...
transfection of wild-type human ASA. Such ASA-expressing control cells released the NBD-fatty acid eluting from the HPLC column as a single peak with a retention time of ~16 min (Fig. 4A). Confirming the TLC data, no such peak could be seen for uncorrected 17−/−A1 cells (Fig. 4B). When the sensitivity of the fluorescence detector was increased, a faint signal was, however, detectable also for mock-transfected 17−/−A1 cells (Fig. 4, C and D, control). When the 13 candidate enzymes were individually expressed in 17−/−A1 cells, none of them but one increased the signal for the NBD fatty acid compared with control cells transfected with empty vector. The exception was FAAH that increased the peak area by a factor of 2.01 ± 0.42 (mean ± SD) in five independent transfection experiments. Overexpression of ASAH1, on the contrary, had no effect (factor 1.12 ± 0.38). Liberation of the NBD fatty acid by FAAH-transfected cells was confirmed by TLC (Fig. 4E). We then generated 17−/−A1 cells stably transfected with either FAAH, or as a control, with ASAH1. Expression levels of single clones were analyzed with a fluorescence-based assay measuring deacylation of AMCAA (for FAAH) and western blotting (for ASAH1), respectively. The clone with the highest FAAH activity, called FAAH-25, released 2.40-fold more NBD fatty acid than control cells on average (Fig. 4D), whereas the clone with the highest ASAH1 expression showed no increase (factor 0.98, not shown). Increased release of NBD fatty acid by FAAH-25 cells could be independently demonstrated by TLC (Fig. 4F).

In vitro activity of recombinant FAAH

To provide further evidence for a possible role of FAAH in the hydrolysis of sulfatide, NBD-labeled sulfatide was reacted with recombinant human FAAH in a cell-free in vitro assay. As a positive control, we used a bacterial SCDase that is known to hydrolyze the N-acyl linkage between fatty acids and sphingosine bases in various GSLs. Both, recombinant SCDase and, to a lower extent, also recombinant FAAH released significant amounts of NBD-labeled fatty acid from NBD sulfatide (Fig. 4G). Importantly, the competitive FAAH-inhibitor URB597 reduced liberation of the fatty acid in the FAAH-catalyzed reaction. The residual turnover of sulfatide in the presence of competitive amounts of inhibitor might be explained by the limited thermostability of URB597 possibly leading to a progressive decline of its inhibitory activity over the applied incubation time of 24 h.

Lyso-sulfatide levels of FAAH-deficient MLD mice

The described experiments suggested that FAAH deacylates NBD sulfatide in vitro. To investigate if FAAH is also involved in the catabolism of (unlabeled) sulfatide in vivo, we constructed mice with a combined deficiency of ASA and FAAH. Furthermore, the mice were transgenic for the cerebroside sulfotransferase catalyzing the last step in the biosynthesis of sulfatide (19). Due to an increased synthesis and lysosomal storage of sulfatide, these mice develop more severe MLD-like disease than conventional ASA knockout mice. If sulfatide were deacylated to lyso-sulfatide by FAAH in vivo, Figure 4. Hydrolysis of translipofected NBD-sulfatide by FAAH. A and B, HPLC profiles of NBD-labelled lipids extracted from medium of translipofected 17−/−A1 cells. Cells that had been metabolically corrected by transfection of wild-type human ASA prior to loading (A) were compared with untransfected cells (B). NBD-labeled fatty acid (NBD-FA) is detectable only for the corrected cells (arrow). C, HPLC signals for NBD-fatty acids following transient transfection of 17−/−A cells with candidate enzymes as indicated. A representative experiment in which FAAH was compared with four other enzymes is shown. The UV profiles obtained in successive HPLC runs are superimposed. Only FAAH increased the background signal. D, HPLC signals for NBD-fatty acids in 17−/−A1 cells transfected with FAAH and empty expression vector as a control, respectively. Profiles of four technical replicates are shown. E, TLC of lipid extracts from medium of 17−/−A cells. A signal for NBD-fatty acid is visible after transient transfection of FAAH (tf FAAH, arrow), but not for untransfected cells. As a positive control 17−/−A1 cells were metabolically corrected by transfection of human ASA. As a further control NBD sulfatide was incubated with recombinant bacterial sphingolipid ceramide N-deacetylase (SCDase) in the absence of cells. F, same experiment as shown in (E) with stably transfected 17−/−A1 cells (clone 17−/−A1 FAAH-25). G, cleavage of NBD sulfatide by recombinant human FAAH in a cell-free in vitro assay. The liberated fatty acid is indicated by an arrow. URB597 (‘URB’) partially inhibits the reaction. Bacterial SCDase was used as a positive control. No fatty acid is seen in the absence of enzyme.
FAAH-deficient MLD-mice

FAAH-deficient MLD mice should produce less lyso-sulfatide than FAAH-expressing MLD mice. The quantification of lyso-sulfatide levels in brains of 6-month-old double-deficient mice revealed a significant decline by 18.4% (Fig. 5A), confirming this prediction and thus an in vivo function of FAAH in the sulfatide catabolism. FAAH deficiency did not affect sulfatide levels (Fig. 5B) being approximately two orders of magnitude higher than lyso-sulfatide levels (not shown).

Peripheral neuropathy and life expectancy of FAAH-deficient MLD mice

MLD mice develop a hypertrophic neuropathy characterized by an increased deposition of collagen fibrils in the endoneurial space leading to a thickening of peripheral nerves (19). To evaluate a possible effect of FAAH on the caliber of the sciatic nerve, the nerves were dissected from 16-month-old per mouse combined; Fig. 5C. Compared with the control mice, mean weights were, however, significantly increased to 15.1 mg in MLD mice (expressing FAAH) confirming the previous data for the phrenic nerve (19). If FAAH was eliminated in addition, the hypertrophic neuropathy was further aggravated and the wet weight of the two nerves per mouse reached 20.4 mg on average. Consequently, the existing hypertrophic neuropathy of MLD mice is intensified if FAAH is lacking.

MLD mice develop a paralysis of hindlimbs around age 16 months and their life expectancy is reduced to approximately 16 to 20 months (19). Due to the progressive motor impairments also affecting food and water intake, we sacrificed the mice at age 16 months on humanitarian grounds. By this time point, the casualties of the different experimental groups were recorded. Out of 34 ASA-expressing control mice, one FAAH-positive and one FAAH-negative mouse died at age 15 and 14 months, respectively (not shown). All other control mice reached an age of 16 months. Likewise, only two out of 13 MLD mice (expressing FAAH) died close to the end of the observation period of 16 months (Fig. 5D). FAAH deficiency, however, increased mortality of MLD mice significantly and ten of 20 mice died between ages 8 and 16 months. Thus, lack of FAAH diminishes the reduced life expectancy of MLD mice further. None of the mice developed hindlimb paralysis in the observation period.

Behavioral performance of FAAH-deficient MLD mice

As shown previously, MLD mice develop progressive emotional deficits, hyperactivity, and coordination impairments (20). To evaluate possible effects of FAAH deficiency on these parameters, we used tests appropriate to measure the severity of behavioral alterations typical for MLD mice. For this purpose, we compared swimming velocity, rotarod performance, and open field behavior of (i) wild-type mice (FAAH+/+ ctrl), (ii) FAAH-knockout mice (FAAH−/− ctrl), (iii) MLD mice (FAAH+/+, MLD) and (iv) FAAH-deficient MLD mice (FAAH−/− MLD). All mice were 12 months of age. Importantly, FAAH deficiency alone had no detectable effect on the performance in any of the tests applied (compare the first two bars in the histograms of Fig. 6, A–H). As expected, significant behavioral changes were seen, however, in MLD mice compared with wild-type controls (compare the first with the third bar). Thus, the swimming velocity of MLD mice was severely reduced (Fig. 6A) and rotarod tests revealed deficits in motor coordination and balance (Fig. 6B). Furthermore, open field tests revealed trends for less frequent changes between phases of activity and inactivity (Fig. 6, C and D) with a simultaneous increase of migration distances (Fig. 6E), more frequent transitions between center and border zones of the cage (Fig. 6F), and a trend to spent less time in the corners and more in the center (Fig. 6, G and H). These alterations in the open field behavior were not significant, but in accordance with the previously detected increased anxiety-related exploratory activity of MLD mice (20).

Important conclusions can be drawn from the comparison of FAAH-expressing MLD mice and FAAH-deficient MLD mice (compare the last two bars in the histograms of Fig. 6, A–H).
Anandamide and cytokine levels of FAAH-deficient MLD mice

FAAH is the principal enzyme that degrades the neurotransmitter anandamide (AEA) (21). To evaluate the consequences of FAAH deficiency on the levels of this endocannabinoid, we quantified AEA in total brains of the four cohorts of mice by mass spectrometry. This analysis revealed a significant twofold increase in both groups of FAAH-deficient mice (Fig. 7A). Thus, FAAH deficiency increased AEA concentrations and ASA deficiency had no additional effect on the elevated levels.

To detect possible effects of FAAH deficiency on neuroinflammation typical of MLD-mice approaching 2 years of age (22), we evaluated the cytokine profiles of the four mouse cohorts at age 16 months. In this investigation we included macrophage inflammatory protein-1α (MIP-1α), the first cytokine that is upregulated in the disease progression of MLD mice, five cytokines being elevated at end-stage disease [MIP-1β, monocyte chemotactic protein-1 (MCP-1), RANTES, interleukin-1β, interleukin-6], and the two classical proinflammatory cytokines tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) both of which remain unchanged in MLD mice (22). The measurements reproduced part of our previous findings by showing significant upregulation of the lead cytokine MIP-1α in MLD mice compared with wild-type controls (Fig. 7B). Importantly, the absolute levels of this chemokine were indistinguishable between FAAH-expressing and FAAH-deficient MLD mice. Also for the other seven cytokines identical levels were measured in FAAH-expressing and FAAH-deficient MLD mice (not shown). In contrast to MIP-1α, none of them was significantly upregulated in any of the two groups of MLD mice compared with non-MLD controls. Thus, FAAH deficiency did not enhance the early stage of neuroinflammation seen in the present study.

Discussion

Loading assays, based on the addition of radioactively labeled sulfatide to the medium of cultured patient cells, is a sensitive method to evaluate the metabolism of sulfatide and a classical means to diagnose MLD. To avoid radiolabeled sulfatide being expensive and increasingly difficult to obtain, we used fluorescently labeled NBD sulfatide for cell loading. After separation on TLC plates the limit of detection was as low as 10 fmol per band and thus lower than for 3H- or 14C-labeled sulfatide (data not shown). To further elevate the sensitivity of

Whereas FAAH deficiency has no impact on the low swimming velocity of MLD mice (Fig. 6A), it further worsened the weak rotarod performance and the time it took the mouse to fall off the rod was reduced by an additional ~30% (Fig. 6B). Additional effects of FAAH deficiency became apparent also in the open fields tests. Here, FAAH-deficient MLD mice switched ~2.5fold more often between phases of activity and inactivity, which led to a formal normalization of this parameter (Fig. 6, C and D). Notably, the shift to shorter walks and shorter breaks did not affect the total distances covered by the mice within the observation period (Fig. 6E). It did, however, correlate with a tendency for an increased mobility between the different zones of the cage (Fig. 6F) and the time spent in the corners was further reduced (Fig. 6, G and H).

Figure 6. Behavioral tests. Bars represent means ± SEM of n = 13 to 16 mice per group. The indicated groups of 12-month-old mice were compared by Student’s t test and the p-values are indicated. A, swimming velocity. For each mouse the average speed was calculated from the three consecutive trials. B, rotarod performance. The statistics includes the individual times mice were able to stay on the accelerating rotarod (latency to fall) in the four consecutive trials. C, frequency of activity. Activity used as a measure for mobility is defined as a movement that causes a total pixel change of the recorded body shape above a certain threshold. D, frequency of inactivity state. Is different from (C) due to another threshold value used to define inactivity. E, distance moved. Total length of the path covered by each mouse within 30 min. F, frequency of zone transitions. This is the number of times a mouse moves from one of three defined zones (center, border, corner) to another zone. G, center duration. Cumulative time that the mouse spent in the center zone of the arena. H, corner duration. Cumulative time spent in the four corner zones of the arena.
lyso-sulfatide production. Additional experiments are required to find out if other sulfatide-hydrolyzing endo-N-deacylases exist and/or if de novo synthesis by sulfation of psychosine via the galactose-3-sulfotransferase-1 plays a major role in lyso-sulfatide formation (9) (Fig. 8).

FAAH is a component of the endocannabinoid system comprising endocannabinoids acting as retrograde neurotransmitters, cannabinoid receptors signaling through G-proteins and hydrolases terminating the action of released endocannabinoids by enzymatic cleavage (21). FAAH hydrolyzes the endocannabinoid AEA (N-arachidonoyl ethanolamine) to arachidonic acid and ethanolamine. The enzyme is, however, quite promiscuous and accepts substrates of varying fatty acid chain length, degree of saturation, and head group structure (23). Although sulfatide might fall into the broad spectrum of FAAH substrates, it has not been identified as such to date. FAAH is present in the brain, liver, kidney, and many other tissues. Also, primary macrophages and microglia express FAAH (24–27). At first glance, a role of FAAH in the catabolism of sulfatide is surprising as FAAH is not lysosomal but an integral membrane protein of the ER. Sulfatide is synthesized from galactosylceramide in the Golgi apparatus (28), and a direct encounter of FAAH with sulfatide, therefore, seems impossible. Lysosomal storage might, however, result in a translocation of accumulating sulfatide to other cell compartments, especially to the endoplasmic reticulum, as previously suggested for glucosylceramide in the lysosomal storage disease Gaucher disease (29). Such a retrograde transfer from the lysosome to the ER might be accomplished by cytosolic lipid transporters (1) or interorganelle membrane contact sites (12). The crystal structure of FAAH reveals a putative substrate entry channel that is directly accessible for lipids of the ER membrane (30). This might allow access of sulfatide to the active site of the enzyme without the need of prior extraction from the membrane via activator proteins (saposins) that are indispensable for lysosomal degradation (1, 2).

It is striking that FAAH shares features with the aforementioned nonlysosomal sulfatide-hydrolyzing enzyme that has been partially purified from mouse brain (11). Thus, the molecular mass and pI of the latter were reported to be 66 kDa and 7.7, respectively, compared with 67 kDa and 7.8 determined for FAAH (21). Furthermore, both enzymes are non-glycosylated and membrane-bound. It is tempting to speculate that we have reidentified the same enzyme and pathway that has been partially uncovered by a classical biochemical approach more than 2 decades ago. It is even conceivable that the nonlysosomal sulfatide-hydrolyzing enzyme of immortalized human B-cells was de facto FAAH (10). The enzyme neither accepted lyso-sulfatide nor p-nitrocatecholsulfate as a substrate, which, as the authors mentioned, is remarkable for a sulfatase that accepts sulfatide. The substrate specificity would be, however, logical for an endo-N-deacylase as both substrates are devoid of an N-linked fatty acid.

Another important finding of the present study is that genetic elimination of FAAH activity, albeit lowering the lyso-sulfatide level in the CNS, exacerbated the disease phenotype of ASA-deficient MLD mice. Thus, double-deficient mice...
showed a reduced rotard performance, increased anxiety-related exploratory activity, aggravated peripheral neuropathy, and reduced life span compared with conventional MLD mice. The more severe phenotype in the presence of reduced lyso-sulfatide levels cannot be explained by the common pathophysiological model of glycosphingolipidoses. This model claims that the lyso-forms of the accumulating GSLs are cytotoxic and promote the progression of disease by disturbing signal transduction pathways, energy homeostasis, and other cellular processes (4). Aggravation of the disease phenotype is also difficult to explain in view of the known anti-inflammatory and neuroprotective effects exerted by inhibition of FAAH activity in many animal models of neurological diseases (31). Aggravation of the disease phenotype is also difficult to explain in view of the known anti-inflammatory and neuroprotective effects exerted by inhibition of FAAH activity in many animal models of neurological diseases (31). Only recently, it has been shown, for example, that oral treatment of sphingomyelinase-deficient mice (model of the lysosomal storage disease Niemann–Pick type A/B) with FAAH inhibitors alleviated neuroinflammation, retarded neurodegeneration, improved behavioral alterations, and extended life span (32). To find a possible explanation for the severe phenotype of FAAH-deficient MLD mice, we quantified AEA and cytokines in total brain. The measurement of cytokines did, however, not reveal any evidence that FAAH deficiency enhances the neuroinflammatory process typical of aged MLD mice (22). Likewise, ASA deficiency has no additional effect on the increased AEA level of FAAH-deficient mice. Thus, there is no obvious explanation for the more severe phenotype of double-deficient mice to date. Cytotoxic effects of AEA have been described (33, 34), and it might be speculated that certain brain cell types are particularly vulnerable to AEA-induced apoptosis if they are predamaged by sulfatide or lyso-sulfatide storage. Alternatively, FAAH deficiency might cause the formation of a lipid species with higher cytotoxicity than lyso-sulfatide. Shotgun lipidomics or LC-MS analysis of lipids would be most straightforward to identify such a hypothetical compound. Clearly it would be of interest to evaluate why a reduction of the FAAH activity has deleterious effects in MLD mice, but ameliorates the disease phenotype of mouse models of other CNS diseases (31). It would also be interesting to analyze if supraphysiological FAAH activities have the opposite effect and mitigate the disease progression in MLD mice. Because allosteric activators of FAAH are not known, this question has to be addressed by transgenic overexpression of FAAH in the MLD background.

Experimental procedures

Cells

Two immortalized astrocytoma cell lines, wild-type 11+/+C1 cells and ASA-deficient 17−/−A1 cells, were used (13). Unless otherwise indicated they were cultured in Dulbecco’s modified Eagle’s medium (DMEM) without phenol red (Thermo Fisher Scientific, cat. no. 31053044). ASA-deficient mixed brain cell cultures and microglial cells were isolated from the brains of newborn ASA knockout mice (35). ASA-deficient macrophages were prepared from bone marrow of adult ASA knockout mice (36) using Fischer’s medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin (all from Thermo Fisher Scientific), and 50 ng/ml macrophage colony stimulating factor (Peprotech).

cDNAs and cloning of expression plasmids

E.coli stab cultures were purchased from Invitrogen and ImaGenes-SourceBioscience, respectively (Table S1). Plasmid DNA was prepared by standard methods and the cDNA inserts were sequenced in both directions (Eurofins Genomics). Sequence-verified full-length cDNAs were PCR-cloned into the eukaryotic expression plasmid pcDNA3 (Thermo Fisher Scientific). A double-stranded DNA sequence encoding a C-terminal myc-tag preceded by a Ser-Gly4-Ser linker was synthesized by annealing of two complementary oligonucleotides (Eurofins Genomics) and cloned in frame to generate

Figure 8. Model of the lyso-sulfatide metabolism combining established and hypothetical pathways. Sulfation of psychosine by the galactose-3-sulfotransferase-1 has been proposed by Lin and Horowitz (9). ASA converts lyso-sulfatide to psychosine (45). For further details, see main text.
**FAAH-deficient MLD-mice**

myc-tagged proteins. Exceptions were ASAHI, NAAA, and FAAH, which were expressed as untagged proteins to avoid interference with proteolytic processing and/or hydrolytic activity suggested by published data. The plasmid pcDNA3-ASA-myc harboring the myc-tagged full-length human ASA cDNA was cloned accordingly. The transmembrane domain of the exoenzyme DPEP1 was deleted to obtain a soluble enzyme variant. All cDNAs were of human origin except NAAA, for which only a murine full-length clone was available.

**Transfection and western blotting**

17−/− A1 astrocytoma cells were transiently transfected with Turbofect (Thermo Fisher Scientific) following the instructions of the manufacturer. To generate stably transfected cells, 500 μg/ml G418 disulfate (VWR Chemicals) was added to the medium for 10 to 14 days and growing single clones were isolated by aspiration with a pasteur pipette. Transgene expression of transfected cells was verified by immunoblotting using anti-myc antibodies and, for ASAHI, NAAA, and FAAH, protein-specific antibodies, respectively. The following primary antibodies and dilutions were used: (i) mouse monoclonal α-c-myc antibody 9e10 (Santa Cruz; sc-40; 1:5000); (ii) goat polyclonal α-FAAH V-17 antiserum (Santa Cruz, sc-26427, 1:1000); (iii) goat polyclonal α-ASAHL (NAAA) G-13 antiserum (Santa Cruz, sc-104081, 1:200); (iv) rabbit polyclonal α-ASAHI antiserum (kindly provided by K. Sandhoff, Bonn, Germany; 1:1000). The following secondary antibodies were used: (i) peroxidase-conjugated bovine α-goat antibodies (Dianova; 805-035-180; 1:10,000); (ii) peroxidase-conjugated goat α-rabbit antibodies (Dianova, 111-035-003; 1:10,000).

**Sulfatide loading and lipid extraction**

The GSL metabolism of cultured cells was analyzed using the sulfatide fluorescent analogue N-[12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl]-cerebroside 3-sulfate (NBD-sulfatide; Matreya). In this compound the NBD fluorophore is linked to the terminal (omega) carbon atom of the N-linked fatty acid. In general, 5 nmol NBD sulfatide was added to subconfluent cells in a 35 mm dish. For transfection, 5 nmol NBD sulfatide was dissolved in 1.5 μl methanol and mixed with 1.5 μl FuGENE HD transfection reagent (Promega) prior to loading. In pretests also TurboFect, ExGen 500, and Lipofectamine 2000 transfection reagent were used instead of FuGENE (all from Thermo Fisher Scientific). Loading by complexation with bovine serum albumin (BSA) and synthetic low-density lipoproteins (sLDL) was as described (37, 38). After incubation for 6 h at 37 °C, cells were washed and cultured with fresh medium for 18 h. Then, total lipid was isolated from cells and/or conditioned medium by solid-phase extraction using self-made RP-18 LiChroprep (Merck) columns with 2 ml bed volume prewashed once with 1 ml methanol and twice with 1 ml H2O bidest each. After loading the samples, the flow-through was discarded and the columns were washed four times with 1 ml each of 4 mM hydrochloric acid. Lipids were eluted with 6 ml chloroform/methanol 1:1 (v/v) and dried under a nitrogen stream. The dry lipids were dissolved in 200 μl chloroform/methanol 1:1 (v/v) for separation by thin-layer chromatography (TLC) and in 250 μl methanol/H2O bidest/85% phosphoric acid 550:450:1.5 (v/v/v) for separation by HPLC, respectively.

**Lipid analysis**

For TLC, appropriate volumes of lipid extracts were applied to high-performance TLC plates (Merck) with an automatic TLC sampler 4 (CAMAG). Separation was with chloroform/methanol/acetic acid 190:9:1 (v/v/v) as solvent system. NBD sulfatide (Matreya), NBD galactosylceramide (Avanti Polar Lipids), and NBD dodecanoic acid (Invitrogen-Thermo Fisher Scientific) were coseparated as standards. Metabolic products harboring an NBD-labeled fatty acid were identified with a FLA-5100 fluorescence scanner (Fujifilm Life Science) at an excitation and emission wave length of 473 and 537 nm, respectively. For HPLC, a Bio-Tek HPLC system (Kontron AG) equipped with a Zorbax C18-column (2.1 mm × 150 mm; Agilent Technologies) and an FP-2020 fluorescence detector (Jasco) was used. The wavelength for excitation was 465 nm and for emission 535 nm. Mobile phases consisted of methanol/H2O bidest in different volume fractions: (A) 550:450:1.5, (B) 750:250:1.5, (C) 1000:0:1.5. For the separation of lipids, the column was run with a constant flow rate of 0.5 ml/min at room temperature. The gradient cycle was 50 min in length with a 5 min isocratic segment with solvent (A), a 15 min linear gradient to solvent (B), a 15 min isocratic segment with solvent (C), and a 15 min isocratic segment with solvent (A). Lyso-sulfatide and sulfatide levels of mouse brain were quantified by mass spectrometry on a Xevo TO-S triple quadrupole mass spectrometer (Waters GmbH) (39) and TLC, respectively (40).

**Anandamide analysis**

AEA levels of total brain were analyzed by LC–mass spectrometry (MS) essentially as described (41) using deuterated AEA (AEA-d8) as an internal standard (Cayman Chemical). Following extraction with acetonitrile (ACN), AEA chromatography was performed on a Dionex Ultimate 3000 RSLC nano HPLC system (Dionex GmbH). The autosampler was operated in μl-pickup mode. Dried extracts were dissolved in 10 μl 95% ACN, 0.1% formic acid (FA). Solvent A was 0.1% FA. Two microliter was injected onto a C18 analytical column (self-packed 300 mm length, 75 μm inner diameter, ReproSil-Pur 120 C18-AQ, 3 μm, Dr Maisch GmbH) equilibrated with 35% solvent B (90% ACN, 0.1% FA). AEA was separated during a linear gradient from 35% to 98% solvent B at 400 nl/min. The nanoHPLC was coupled online to an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific). Ions between 200 and 600 m/z were scanned and captured in the Orbitrap detector every 3 s with a resolution of 60,000 at m/z = 200 (maximum fill time 50 ms, AGC target 400,000). In a parallel reaction monitoring method, selected ions ([d8-AEA+H]+, 356.3399 Da; [d8-AEA+Na]+, 378.3219 Da; [AEA+H]+, 348.2897 Da; [AEA+Na]+, 370.2717 Da) were subjected to higher-energy CID (HCD, 0.7 Da quadrupole isolation, threshold,
normalized energy 30%) and fragments analyzed in the Orbitrap analyzer (resolution 7500, maximum fill time 22 ms, target 50,000). Data analysis was done with Skyline (42) software using areas of extracted ion chromatograms of two most abundant precursor isotope masses and a product ion: 62.0600 Da or 62.0663 Da for endogenous or d8-AEA respectively. Typical mass deviation was <2 ppm (MS1) and <15 ppm (MS2). The abundance ratio between AEA and d8-AEA was used for determination of AEA quantities. Technical replicates with highest signal-to-noise ratios of internal standard were used.

Cytokine analysis

Brains were dissected, cut midsagittally, and one hemisphere (about 200 mg wet weight) was homogenized in 2 ml ice-cold phosphate-buffered saline (PBS) pH 7.4 supplemented with Halt protease inhibitor cocktail (Thermo Fisher Scientific) and 5 mM EDTA using an Ultra-Turrax T25 homogenizer (Janke & Kunkel). Homogenates were centrifuged for 5 min at 10,000g and 4°C. Protein concentrations of the supernatants were determined using the Bio-Rad DC assay (Bio-Rad). Cytokine levels were measured with ABTS-ELISA kits according to the manufacturer’s recommendations (Peprotech). For the ELISAs appropriate volumes of the supernatant supplemented with 0.05% Tween-20 were used. Homogenates of 3 to 5 mice per group and eight dilutions of each cytokine standard were measured in duplicates. The resulting calibration curves were used to determine the cytokine levels that were subsequently normalized on the corresponding protein concentration of the homogenate.

Life-cell fluorescence microscopy

Cells were loaded with the Golgi marker Invitrogen BODIPY TR ceramide (Thermo Fisher Scientific) for 30 min according to the recommendations of the manufacturer. Then, the cells were washed and BODIPY 500/510-labeled sulfatide was loaded by translocation as described before. The labeled sulfatide was synthesized by standard methods from lysosulfatide and BODIPY 500/510 C12-fatty acid (Thermo Fisher Scientific) (14). Fluorescence was monitored in an Axiocert 200M inverted microscope equipped with appropriate fluorescence filters, an AxioCam MRc camera in monochrome mode and the AxioVision 4.8.2. software (all from Carl Zeiss).

Enzymes and cell-free in vitro assays

Recombinant human FAAH expressed in Sf21 insect cells was from Cayman Chemicals. The activity of FAAH was measured with 7-amino-4-methyl coumarin arachidonoyl amide (AMCA, Cayman Chemicals) that is cleaved to arachidonic acid and highly fluorescent 7-amino-4-methyl coumarin (43). To test FAAH-catalyzed hydrolysis of sulfatide, NBD sulfatide (1 nmol) was dried in a stream of nitrogen, dissolved in 2 μl methanol, and mixed with 200 μl FAAH reaction buffer (125 mM Tris-HCl pH 9.0, 1 mM EDTA, 4.7 mM sodium taurodeoxycholate) by ultrasonication. After adding four units of recombinant human FAAH, the mixture was incubated for 24 h at 37 °C. The reaction was stopped and lipids were extracted with 1 ml chloroform/methanol 1:1 (v/v). Following vigorous vortexing and phase separation by centrifugation, the organic phase was collected and dried under a stream of nitrogen. The residue was dissolved in 200 μl chloroform/methanol 1:1 (v/v) and analyzed by TLC. As a negative control, the competitive FAAH-inhibitor URB597 (Cayman Chemicals) was added at a final concentration of 1 μM. As a positive control for the decarboxylation reaction under investigation, bacterial sphingolipid ceramide N-deacylase (SCDase; Takara) was used in FAAH reaction buffer without sodium taurodeoxycholate. SCDase efficiently hydrolyzes the N-acyl linkage between the fatty acid and sphingosine base of GSLs, including NBD sulfatide (see Fig. 4, E and G).

Mice

Mice with a deficiency of murine ASA (mASA−/−) being double transgenic (tg) for cerebroside sulfotransferase (PLP-CST) and the inactive human ASA (hASA) mutant hASAc69s represent an aggravated mouse model of MLD (19). For reasons of simplicity, they are here briefly designated as MLD-mice. They were crossed with FAAH knockout mice (FAAH−/−; kindly provided by Andreas Zimmer, Bonn, Germany) to generate four genotype combinations: (i) FAAH−/− mASA−/− hASAc69s tg PLP-CST tg (FAAH-deficient MLD-mice); (ii) FAAH+/+ mASA−/− hASAc69s tg PLP-CST tg (FAAH-expressing MLD-mice); (iii) FAAH−/− mASA± hASAc69s tg PLP-CST tg (FAAH-deficient control mice); (iv) FAAH+/+ mASA± hASAc69s tg PLP-CST tg (FAAH-expressing control mice). Thus, all four groups were double transgenic for CST and hASAc69s and differed by the combination of FAAH and mASA knockout alleles. Animals were maintained on a 12-h-light and 12-h-dark schedule with ad libitum access to food and water. Mice were kept according to the German “Tierschutzgesetz” and the European Union directive 2010/63/EU on the protection of animals used for scientific purposes. Breeding, handling, and investigation of the mice were approved by the local authorities (permit no. 84-02.04.2016.A394; Landesamt für Natur, Umwelt und Verbraucherschutz). To evaluate the degree of hypertrophic neuropathy, sciatic nerves of full length were dissected from female mice (44), the two nerves per mouse were combined, and their wet weights were determined by weighing on an analytical balance.

Behavioral tests

Mouse behavior was tested at an age of 12 months. All 63 mice analyzed (13–18 mice per group) were born in a small time interval of 16 days. They were trained and tested one by one in a fixed order on identical days. Motor coordination was evaluated using a rotarod apparatus (Ugo Basile, Model 47600) at an accelerated speed mode with a ramp duration of 300 s and a minimum and maximum speed of 4 and 40 rpm/min, respectively. Mice were accustomed to the task on four consecutive days at a constant speed of 4 rpm for 2 min. On
FAAH-deficient MLD-mice

each of the following 4 days the mice were tested at the accelerating speed mode once. The time spent on the rotarod (latency to fall) was recorded. The swimming velocity was measured in a self-constructed opaque swimming pool with the dimensions $150 \times 10 \times 15$ cm ($\text{length} \times \text{width} \times \text{height}$). The water temperature and depth were $26$ °C and $10$ cm, respectively. An accessible platform of $10 \times 10$ cm was placed at one end of the lane and allowed the mice to get out of the water. The mice were first trained on four consecutive days to swim increasing distances to the platform following a light gradient from bright to dark (one trial per day). On the following 3 days, mice were put into a $10 \times 10$ cm starting area opposite to the platform and filmed with a video camera from above. The time needed to cover the last $100$ cm to the platform was extracted from the recordings and the swimming velocity (m/s) was calculated. Motor activity, anxiety-related responses, and exploratory activities were analyzed by open field tests using a dimly lit arena measuring $30 \times 30$ cm ($30$ cm high) divided into a wall zone ($7 \times 7$ cm), a corner zone ($7 \times 7$ cm), and a center zone ($16 \times 16$ cm). Mice were placed into the center of the arena and tracked for $30$ min using a computer-operated EthoVision camera system and the EthoVision XT9 software (Noldus Information Technology).

Data availability

The authors confirm that the data supporting the findings of this study are available within the article, its supporting materials, and from the corresponding author, Ulrich Matzner (Institute of Biochemistry and Molecular Biology, Medical Faculty, University of Bonn, Email: matzner@uni-bonn.de) upon reasonable request, respectively.

Supporting information—This article contains supporting information (17).

Acknowledgments—We thank Dr Günter Schwarzmann for synthesizing BODIPY-labeled sulfatide, Prof. Dr Andreas Zimmer for making FAAH knockout mice available, and Prof. Dr Konrad Sandhoff for providing antibodies (all from Bonn, Germany). We are also grateful to Prof. Dr Stephan Baader and Daniela Krauss (both Bonn, Germany) for their behavioral tests and generous assistance in the animal facility. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author contributions—U. M. conceptualization; M. S. and U. M. data curation; C. Y., B. G., M. S., and U. M. formal analysis; C. Y., B. G., M. S., and U. M. investigation; B. G., M. S., and U. M. methodology; V. G. and U. M. project administration; V. G. and U. M. supervision; U. M. visualization; U. M. writing—original draft; B. G. and M. S. writing—review and editing.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: ACER1, alkaline ceramidease-1; ACY1, aminoacylase; AEA, anandamide; AMCA, 7-amino-4-methyl coumarin arachidonoyl amide; ASA, arylsulfatase A; ASAH1, acid ceramidease; ASAH2, neutral ceramidease; BSA, bovine serum albumin; CPVL, carboxypeptidase A; CT, cerebroside sulfotransferase; CTSB, cathepsin B; CTSH, cathepsin H; CTSS, cathepsin S; CTSZ, cathepsin Z; DPEP1, dipeptidase I; FAAH, fatty acid amide hydrolase; GALK, galactosylceramide; GSL, glycosphingolipid; hASA, human ASA; HPLC, high-performance liquid chromatography; mASA, murine ASA; MIP-1α, macrophage inflammatory protein-1α; MLD, metachromatic leukodystrophy; NAAA, N-acylethanolamine-hydroryzing acid amidae; NBD, nitrobenzoxadiazole; SCDA, sphingolipid ceramide N-deacylase; SCPEP1, carboxypeptidase C; sLDL, synthetic low-density lipoprotein; tg, transgenic; TLC, thin-layer chromatography.

References

1. Schulze, H., and Sandhoff, K. (2014) Sphingolipids and lysosomal pathologies. Biochim. Biophys. Acta 1841, 799–810
2. Breiden, B., and Sandhoff, K. (2019) Lysosomal glycosphingolipid storage diseases. Annu. Rev. Biochem. 88, 461–485
3. von Figura, K., Gieselmann, V., and Jaeken, J. (2001) Metachromatic leukodystrophy. In: Scrivier, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., Vogelstein, B., eds. The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, New York, NY, 3695–3724
4. Suzuki, K. (1998) Twenty five years of the “psychosine hypothesis”: A personal perspective of its history and present status. Neurochem. Res. 23, 251–259
5. Hannun, Y. A., and Bell, R. M. (1987) Lysosphingolipids inhibit protein kinase C: Implications for the sphingolipidoses. Science 235, 670–674
6. Toda, K., Kobayashi, T., Goto, I., Kurokawa, T., and Ogomori, K. (1989) Accumulation of lysosulfatide (sulfogalactosylsphingosine) in tissues of a boy with metachromatic leukodystrophy. Biochem. Biophys. Res. Commun. 159, 605–611
7. Hans, M., Pusch, A., Dai, L., Racke, K., Swandulla, D., Gieselmann, V., and Kappler, J. (2009) Lysosphatidate regulates the motility of a neural precursor cell line via calcium-mediated process collapse. Neurochem. Res. 34, 508–517
8. van Eijk, M., Ferraz, M. J., Boot, R. G., and Aerts, J. M. F. G. (2020) Lyso-glycosphingolipids: Presence and consequences. Essays Biochem. 64, 565–578
9. Lin, Y. N., and Horowitz, M. I. (1982) Cerebroside sulfotransferase in rat gastric mucosa. Int. J. Biochem. 14, 831–838
10. Tempesta, M. C., Salvayre, R., and Levade, T. (1994) Functional compartments of sulphatide metabolism in cultured living cells: Evidence for the involvement of a novel sulphatide-degrading pathway. Biochem. J. 297, 479–489
11. Sundaram, S. K., Fan, J. H., and Lev, M. (1995) A neutral galactocerebroside sulfate sulfatidase from mouse brain. J. Biol. Chem. 270, 10187–10192
12. Henne, W. M. (2017) Discovery and roles of ER-endolysosomal contact sites in disease. Adv. Exp. Med. Biol. 997, 135–147
13. Habetha, M. (2001) Sulfatide does not induce apoptosis in arylsulfatase A-deficient cells. Neurosci. Res. Commun. 29, 69–77
14. Schwarzmann, G. (2018) Synthesis of fluorescent gangliosides. Methods Mol. Biol. 1804, 323–356
15. Pohl, A., Lage, H., Müller, P., Pomorski, T., and Herrmann, A. (2002) Transport of phosphatidylserine via MDR1 (multidrug resistance 1)
P-glycoprotein in a human gastric carcinoma cell line. Biochem. J. 365, 259–268

16. Polten, A., Fluharty, A. L., Fluharty, C. B., Kappler, J., von Figure, K., and Gieselmann, V. (1991) Molecular basis of different forms of metachromatic leukodystrophy. N. Engl. J. Med. 324, 18–22

17. Lühlke, T., Lobel, P., and Sleat, D. E. (2009) Proteomics of the lysosome. Biochim. Biophys. Acta. 1793, 625–635

18. Furusato, M., Sueyoshi, N., Mitsutake, S., Sakaguchi, K., Kita, K., Okino, N., Ichinose, S., Omori, A., and Ito, M. (2002) Molecular cloning and characterization of sphingolipid ceramide N-deacylase from a marine bacterium, Shewanella alga G8. J. Biol. Chem. 277, 17300–17307

19. Ramakrishnan, H., Haydary, K. K., Lüllmann-Rauch, R., Wessig, C., Fewou, S. N., Maier, H., Goebel, H. H., Gieselmann, V., and Eckhardt, M. (2007) Increasing sulfatide synthesis in myelin-forming cells of arylsulfatase A-deficient mice causes demyelination and neurological symptoms reminiscent of human metachromatic leukodystrophy. J. Neurosci. 27, 9482–9490

20. Matthes, F., Stroobants, S., Gerlach, D., Wohlenberg, C., Wessig, C., Fogh, J., Gieselmann, V., Eckhardt, M., D’Hooge, R., and Matzner, U. (2012) Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age. Hum. Mol. Genet. 21, 2599–2609

21. Lu, H. C., and Mackie, K. (2016) An introduction to the endogenous cannabinoid system. Biol. Psychiatry 79, 516–525

22. Stein, A., Stroobants, S., Gieselmann, V., D’Hooge, R., and Matzner, U. (2015) Anti-inflammatory therapy with simvastatin improves neuroinflammation and CNS function in a mouse model of metachromatic leukodystrophy. Mol. Ther. 23, 1160–1168

23. Lang, W., Qin, C., Lin, S., Khanolkar, A. D., Goutopoulos, A., Fan, P., Abouzid, K., Meng, Z., Biegel, D., and Makriyannis, A. (1999) Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J. Med. Chem. 42, 896–902

24. Maccarrone, M., van der Stelt, M., Rossi, A., Veldink, G. A., Vliegenthart, J. F., and Agrò, A. F. (1998) Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. 273, 32332–32339

25. Di Marzo, V., Bisegno, T., De Petrocellis, L., Melck, D., Orlando, P., Wagner, J. A., and Kunos, G. (1999) Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264, 258–267

26. Tanaka, M., Yagyu, K., Sackett, S., and Zhang, Y. (2019) Anti-Inflammatory effects by pharmacological inhibition or knockdown of fatty acid amide hydrolase in BV2 microglial cells. Cells 8, 491

27. Stella, N. (2009) Endocannabinoid signaling in microglial cells. Neuropharmacology 56, 244–253

28. Yaghootfam, A., Sorkalla, T., Häberlein, H., Gieselmann, V., Kappler, J., and Eckhardt, M. (2007) Cerebroside sulfotransferase forms homodimers in living cells. Biochemistry 46, 9260–9269

29. Elleder, M. (2006) Glucosylceramide transfer from lysosomes—the missing link in molecular pathology of glucosylceramidase deficiency: A hypothesis based on existing data. J. Inherit. Metab. Dis. 29, 707–715

30. McKinney, M. K., and Cravatt, B. F. (2005) Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74, 411–432

31. Ren, S. Y., Wang, Z. Z., Zhang, Y., and Chen, N. H. (2020) Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. Acta Pharmacol. Sin. 41, 1263–1271

32. Bartoll, A., Toledano-Zaragoza, A., Casas, I., Guzmán, M., Schuchman, E. H., and Ledesma, M. D. (2020) Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling. EMBO Mol. Med. 12, e11776

33. Schwarz, H., Blanco, F. J., and Lotz, M. (1994) Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 55, 107–115

34. Maccarrone, M., Lorenzon, T., Bari, M., Melino, G., and Finazzi-Agro, A. (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275, 31938–31945

35. Kaminski, D., Yaghoobfatm, C., Matthes, F., Feick, J., Gieselmann, V., and Matzner, U. (2021) Brain cell type-specific endocytosis of arylsulfatase A identifies limitations of enzyme-based therapies for metachromatic leukodystrophy. Hum. Mol. Genet. 29, 3807–3817

36. Zhang, X., Goncalves, R., and Mosser, D. M. (2008) The isolation and pharmacology of the P-selectin glycoprotein ligand-1 ligand, an endogenous cannabinoid receptor agonist. J. Pharmacol. Exp. Ther. 326, 668–675

37. Monti, E., Preti, A., Novati, A., Aleo, M. F., Clemente, M. L., and Marchesini, S. (1992) Uptake and metabolism of a fluorescent sulfatide analogue in cultured skin fibroblasts. Biochim. Biophys. Acta 1124, 80–87

38. Zanette, D., Hooge, R., and Matzner, U. (2021) Brain cell type-specific endocytosis of arylsulfatase A identifies limitations of enzyme-based therapies for metachromatic leukodystrophy. Hum. Mol. Genet. 29, 3807–3817

39. Mirzaian, M., Kramer, G., and Porrath, B. J. (2015) Quantification of sulfatides and lysosulfatides in tissues and body fluids by liquid chromatography-tandem mass spectrometry. J. Lipid Res. 56, 936–943

40. Matzner, U., Herbst, E., Haydary, K. K., Lüllmann-Rauch, R., Wessig, C., Schröder, S., Eistrup, C., Möller, C., Fogh, J., and Gieselmann, V. (2005) Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum. Mol. Genet. 14, 1139–1152

41. Chen, J., Paudel, K. S., Derbenev, A. V., Smith, B. N., and Stinchcomb, A. L. (2009) Simultaneous quantification of anandamide and other endocannabinoids in dorsal vagal complex of rat brainstem by LC-MS. Chromatographia 69, 1–7

42. Pino, L. K., Searle, B. C., Bollinger, J. G., Nunn, B., and MacCoss, M. J. (2020) The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomics. Mass Spectrom. Rev. 39, 229–244

43. Ramao, M. K., Murphy, E. A., Shen, M. W., Wang, Y., Bushell, K. N., Huang, N., Pan, N., Williams, C., and Clark, J. D. (2005) A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening. Anal. Biochem. 343, 143–151

44. Bala, U., Tan, K. L., Ling, K. H., and Cheah, P. S. (2014) Harvesting the maximum length of sciatic nerve from adult mice: A step-by-step approach. BMC Res. Notes 7, 714

45. Breiden, B., and Sandhoff, K. (2019) Emerging mechanisms of drug-induced phospholipidosis. Biol. Chem. 401, 31–46